ISSN: 2320-5407
Int. J. Adv. Res. 8(06), 1260-1265
Journal Homepage: -www.journalijar.com
Article DOI:10.21474/IJAR01/11213
DOI URL: http://dx.doi.org/10.21474/IJAR01/11213
RESEARCH ARTICLE
ROLE OF VITAMIN E IN PREVENTION OF CHEMOTHERAPY INDUCED PERIPHERAL
NEUROPATHY
Dr. Asif Riaz Khan, Dr. Fauzia Abdus Samad, Dr. Syed Abdus Samad, Dr. Anum Khan, Dr. Sharmin Arif
and Dr. Rimsha Zahid
Medical Oncology Department, Fauji Foundation Hospital Rawalpindi, Pakistan 46000.
……………………………………………………………………………………………………....
Manuscript Info
Abstract
…………………….
………………………………………………………………
Manuscript History
Received: 20 April 2020
Final Accepted: 25 May 2020
Published: June 2020
Background: Chemotherapy induced peripheral neuropathy (CIPN) is
one of the commonest and disabling side effect of chemotherapy drugs
like taxanes , platinum compounds, vinca alkaloids, thalidomide and
bortezomib.It often leads to dose reduction and discontinuation of
treatment. Many agents like Vitamin E, glutathione, glutamate, acetyl L
carnityle have been evaluated for their role in prevention of CIPN
without any significant success Hence, CIPN is an important area of
research due to lack of effective agent to prevent CIPN. Methodology:
Un-blind double arm interventional study
Results: Forty patients were distributed in two groups; intervention
(vitamin E supplemented n=20) and control (n=20) arms. The TNSn
scores were comparable at baseline and immediately after
chemotherapy among both groups. However, after 3 months of
chemotherapy the mean TNSn was comparatively low in the
intervention arm (0.95 versus 1.64) which was not statistically
significant. In subset analysis of Paclitaxel-Cisplatin combination
chemotherapy subgroup, TNSn scores of two arms immediately post
chemotherapy and at 3 months showed maximum difference between
the arms (p-value, <0.001). In subset of Paclitaxel group, TNSn score
at baseline and after chemotherapy were comparable. However, TNSn
score measured after 3 months of chemotherapy in Intervention arm
normalized, in contrast to non-intervention arm which still had a mean
TNS of 1 with a p-value of 0.001
Conclusions: Our study showed a protective role of vitamin E
profoundly in patients receiving single agent paclitaxel followed by
paclitaxel and cisplatin regimen where the recovery from CIPN was
much better as compared to control arm.
Copy Right, IJAR, 2020,. All rights reserved.
……………………………………………………………………………………………………....
Introduction:-
Chemotherapy induced peripheral neuropathy (CIPN) is one of the commonest and disabling side effect of
cytotoxicmedicines like taxanes , platinum compounds, vinca alkaloids, thalidomide and bortezomib. [1]It is one of
thedose limiting side effects and often leads to dose reduction and discontinuation of treatment. [2][3][4]CIPN may be
seen after treatments of cancers like ovary, breast, colorectal and hematological malignancies in approximately up to
40 % of patients.[3][5][1][6]CIPN is mostly reversible but it can persist in one thirdof the patients.[7]
Corresponding Author:- Dr. Asif Riaz Khan
Address:-Medical Oncology Department, Fauji Foundation Hospital Rawalpindi, Pakistan 46000.
1260
ISSN: 2320-5407
Int. J. Adv. Res. 8(06), 1260-1265
CIPN symptoms are largely sensory in nature including pain, tingling and numbness in gloves and stocking
distribution.[7][8][9][5][1][10] Motor symptoms are less common than sensory symptoms and include distal muscle
weakness, muscle cramps, loss of deep tendon reflexes in ankle and gait dysfunction. Autonomic symptoms are least
common in their presentation and include postural drop in blood pressure, diarrhea and constipation, anhidrosis,
dryness of eyes and mouth.[9][10][8]
The exact mechanism of taxane induced neuropathy is not known. It is hypothesizedthat Taxanes lead toalteration of
micro-tubulin structure of neurons resulting inreducedtransportation of nutrients within the nervesresulting indying
back neuropathy.[8][11]The longest neurons in body are of hand and feet which is the reason CIPN affects in gloves
and stocking distribution.[8]Other possible mechanism of taxane induced neuropathy is toxic effects on mitochondria
in afferent neurons leading to interruption of axonal energy supply leading to sensory neuropathy. [8][11]Cisplatin and
carboplatin affect dorsal root ganglia as their main target structure causing accumulation of platinum in neural
tissue.[8][11]
Agents like Vitamin E, glutathione, glutamate, acetyl L carnityle have been studied to prevent of
CIPN.[6]Antioxidants like Vitamin E has been evaluated and are thought to act by affecting cellular metabolism. [9]It
protects neurons by inhibiting DNA damage and toxins accumulation. Vitamin E in doses ranging from 300 mg to
600 mg per day which has been tolerated well by patients in various studies and no therapyrelated adverse outcomes
were reported.[12] Moreover, it has not been reportedto affect the antitumor activity of chemotherapeutic agents. [13]
CIPN symptoms are usually difficult to describe and quantify.Of all available neuropathy assessment scores, the
total neuropathy score (TNS), developed by Johns Hopkin’s University, is one of the most comprehensive
score[12].TNS assesses sensory, motor and autonomic signs and symptoms along with quantitative assessment of
vibration and perception threshold.[14]TNS has different versions like reduced (TNSr),modified (mTNS), clinical
(TNSc) and nurse (TNSn).We used TNSn for the assessment of peripheral neuropathy after getting permission from
the author to utilize TNS for assessing CIPN, as it has been validated as sensitive tools for assessment of
CIPN.[1][15]TNS values range from 0-20 for TNSn. Two point change is considered as significant in TNS score.[12]
The aim of the study was to study the role vitamin E in preventing or minimizing the severity of CIPN.
Objective:The Objective of this study is, To evaluate the effect of Vitamin E supplementation on the incidence and severity of
chemotherapy induced peripheral neuropathy (CIPN) in patients treated with cytotoxic agents known to cause it.
Operational Definition:
Chemotherapy induced peripheral neuropathy:Chemotherapy induced peripheral neuropathy is development of
sensory, motor or autonomic neuropathy secondary to the use of different chemotherapy agents.[9]
TNS Score:
Total Neuropathy Score is a tool to detect neuropathy by assessing five parameters; sensory, motor, autonomic, pain
sensitivity and vibration threshold.[14]
Material and Methods:It was an open labeltwoarm interventional study, conducted at Oncology Department, Fauji Foundation Hospital,
Rawalpindi. Total duration of study was 12 months. We included 40 patients based on our parent study data.
Patients wererandomized into two arms, interventional and non-interventional, basedon consecutive non-probability
sampling technique. Patients included in our study met following criteria;
1. Patient aged ≥ 18 years
2. Treatment with cisplatin, carboplatin, paclitaxel, containing chemotherapy regimens
3. Performance status 0-2
Patients with following features were excluded from our study;
1. Patients whohad already received chemotherapy.
2. Diabetes with end organ damage
3. Pre-existing peripheral neuropathy
1261
ISSN: 2320-5407
4.
5.
Int. J. Adv. Res. 8(06), 1260-1265
History of CVA
Pregnancy
Chemotherapy regimens included Paclitaxel, Cisplatin or Carboplatin either alone or in combinations. Patients were
recruited from both outpatient and inpatient departments after taking aninformed consent. After detailed history and
examination, staging workup was done as indicated for respective cancers. Patients in intervention arm were given
vitamin E (400 mg/day) prior to starting chemotherapy till one month after completion of chemotherapy cycles.
TNSnwas used to assessCIPN. TNSn assessed five components. Among these sensory, motor and autonomic
componentswere assessed by questionnaire.Pin sensitivity was gauged by neuropen and vibration sensibility was
measured by Rydel-Seiffercalibrated tuning fork.The original TNSn questionnaire was used after taking written
permission from the licensing body which is attached as annex “A”. The two instruments required were specifically
imported from England, on the recommendation of licensing body. Patients in the control arm were not given
vitamin E. TNSn scorewascalculated at baseline before chemotherapy, immediately afterthe completion of
chemotherapy and 3 months later for patients in both intervention and control arms.
SPSS version 23 wasutilized to analyze data.Descriptive analysis included means and standard deviations for
quantitative variables like, age and TNSn Score.Frequencies and percentages were calculated for categorical
variables like tumor types, proportions of intervention arm and different chemotherapy regimens. Inferential
statistics includedthe comparison of mean TNS score among vitamin E intervention and non-intervention groups at
baseline, at the end of chemotherapy regimen and 3 months after last cycle of chemotherapy. Our data was normally
distributed andIndependent student’s t-test was used to compare these means. The p-value of <0.05 was considered
significant. ANOVA was used to compare the TNSn scores between different chemotherapy groups.
Results:In this study a total of 40 patients were distributed in two groups; intervention (vitamin E supplemented with n=20)
and control (n=20) arms. Overall, the mean age of patients was 49.2±7.9years. Commonest diagnosis was ovarian
carcinoma(14 patients, 35.0%), breastcancer (13 patients, 32.5%), carcinoma cervix (7 patients 17.5%) and
endometrial cancer (6 patients 15%). Majority of the patients17 (42.5%) were given Paclitaxel and Cisplatin
combination chemotherapy, followed by paclitaxel alone in 12 patients (30%) and paclitaxel-carboplatin
combination in 11 patients (27.5%) (Table 1).
As per study objective TNSn score was determinedin both vitamin E and control arm. The baseline TNSn level was
0.15 ± 0.36 in vitamin E group and 0.30±1.12 in the control group. The post therapy TNSn level was comparable
among intervention and control group, however, after 3 months of chemotherapy the mean TNSn was comparatively
low in the intervention (0.95 versus 1.64) which was not statistically significant (Table 2). Based on these findings
further subset analyses were conducted.
In subset analysis of Paclitaxel-Cisplatin combination chemotherapy subgroup, TNSn scores of two arms
immediately post chemotherapy and at 3 months showed maximum difference between the arms (p-value, <0.001)as
shown in table 3.In subset of patients receiving Paclitaxel as single agent only, TNSn score at baseline and after
chemotherapy were comparable. However, in this group, TNSn score measured after 3 months of chemotherapy in
Intervention arm normalized, in contrast to non-intervention arm which still had a mean TNS of 1. Moreover, this
difference was also statistically significant with a p-value of 0.001.
Age (years)
< 40
40 to 50
51 or above
Mean ± SD
Diagnosis
Cervical Cancer
Ovarian Cancer
Breast Cancer
Endometrial Cancer
Chemotherapy
Paclitaxel Cisplatin
n (%)
69 (15%)
12(30%)
22(55%)
49.2 ± 7.9
7 (17.5%)
14 (35%)
13 (32.5%)
6 (15%)
17 (42.5%)
1262
ISSN: 2320-5407
Int. J. Adv. Res. 8(06), 1260-1265
Paclitaxel Carboplatin
11(27.5%)
Paclitaxel
12(30%)
Vitamin E intervention
Yes
20 (50%)
No
20(50%)
Table 1:- Overall baseline characteristics of patients (n=40).
Table 2:- TNSn score comparison between intervention and non-intervention groups.
TNSn scores (Mean ± SD)
Vitamin E (n=20)
Control (n=20)
Baseline
0.15 ± 0.36
0.30 ± 1.12
Post chemotherapy
2.6 ± 1.14
2.1 ± 1.41
3 months Post chemotherapy
0.95 ± 0.68
1.60 ± 1.93
p-value
0.57
0.22
0.16
Table 3:- Stratification of TNS score according to chemotherapy regimens in intervention group.
Table 4:- Stratification of TNS score according to chemotherapy regimens in non-intervention group.
TNS
TNS at baseline
TNS after Chemo
TNS 3 months after chemo
Chemotherapy Regimen
Paclitaxel Cisplatin (n=11)
Paclitaxel carboplatin (n=4)
Paclitaxel (n=5)
Paclitaxel Cisplatin (n=11)
Paclitaxel carbo
platin (n=4)
Paclitaxel (n=5)
Paclitaxel Cisplatin (n=11)
Paclitaxel carboplatin (n=4)
Paclitaxel (n=5)
Mean Std. Deviation
0.00 ± 0.00
0.75 ± 0.50
0.00 ± 0.00
3.36 ± 0.80
2.00 ± 0.81
1.40 ± 0.54
1.36 ± 0.50
1.00 ± 0.00
p Value
<0.001
<0.001
<0.001
± 0.00 0.0
Discussion:Cancer survival has improved dramatically due to advancement in treatment modalities. [16] Cancer survival is quoted
to be around 67% in patients above the age of 65 years. [16] Chemotherapy induced peripheral neuropathy (CIPN ) is
one of the adverse effects of chemotherapy which substantially affects quality of life amongcancer
patients.[8]Paclitaxel and platinum compounds like cisplatin and carboplatin have dramatically improved treatment
outcomes at theexpense of disabling adverse effect of neuropathy. [17] So far, there is no known proven therapy which
can prevent onset of CIPN.[18]Hence it is an important area to explore if CIPN can be prevented or minimized
toimprove the quality of life of patients.With this background, we studied the role of Vitamin E in these patients.
Neurotoxicity is dose limiting side effect of paclitaxel with an incidence of up to 60% in patients receiving
paclitaxel.[11]Cisplatin is more neurotoxic than carboplatin. [11] The incidence of neuropathy is almost 60% in
Cisplatin treated patients and combination of paclitaxel and cisplatin has additive effect on the incidence of
neuropathy.[11]
Different drugs and natural compounds have been used for the prevention of CIPN. [3][10][18] Vitamin E has been
reported in literature to have some protective role in prevention of CIPN. [19][20] Vitamin E is believed to have
protective role in reducing neuronal cell destruction secondary to DNA damage and helps to diminish the
accumulation of toxins in dorsal root ganglia. [20][13] Vitamin E was chosen because we could only find six studies
about the role of Vitamin E in preventing CIPN during the literature search from first January 2003 till 31 st
1263
ISSN: 2320-5407
Int. J. Adv. Res. 8(06), 1260-1265
December 2018. Our literature search includedGoogle Scholar, PubMed and ProQuest. Also,Vitamin E is easily
available, with no known interactions with chemotherapy and being well tolerated by patients without any
significant adverse effects.[13] Moreover, no such study has been conducted in Asia-Pacific region.
Argyriou et al studied role of vitamin E in preventing paclitaxel induced neuropathy. [20] The mean age in his study
was 57 years as compared to 49.2 years in our study. Their study included 32 patients with breast, lung and ovarian
cancer. While we had 40 patients in our study cohort who had ovarian, breast, cervical and endometrial carcinoma.
These authors studied the effect of paclitaxel induced peripheral neuropathy in contrast to our study group where
patients receiving chemotherapy regimens including paclitaxel, cisplatin or carboplatin either alone or in
combination were recruited. They used vitamin E 300 mg twice daily while we used vitamin E 400 mg once daily
dose[20]. They assessed neuropathy by neurological symptom score (NSS) while we used TNSn score. They found
positive role of vitamin E in preventing CIPN, while in our study we could appreciate role in early recovery of the
symptoms. In our study both the arms developed almost same severity of neuropathy as demonstrated by mean TNS
score after chemotherapy but at 3 months post chemotherapy, intervention arm had complete resolution of CIPN in
paclitaxel chemotherapy group. The mean TNSn scorein our study was lower in Paclitaxel/Cisplatin arm which
shows beneficial effect in cisplatin induced peripheral neuropathy.
Pace et al investigated role of Vitamin E in Cisplatin induced neuropathy. [19] Their study population was 47 patients
as compared to 40 patients in our study. Their study population average age was 58 years as compared to 49 years in
our study.This was a two arm study.These authors used Vitamin in a dose of 300 mg/day in intervention arm.[19]
Their study population included patients with lung cancer, ovarian cancer, head and neck cancer, urothelial cancer,
gastric and testicular cancer.They reported a lesser incidence and severity of neuropathy in Vitamin E supplemented
arm.[19]Contrary to these results, we did not observe a preventive role of Vitamin E on the incidence of CIPN.
However, early recovery of CIPN was evident by low mean TNSn scores 3 months after chemotherapy. This could
be explained by use of Paclitaxel and Cisplatin combination in our study which was given to 42.5 % population in
contrast to no patient receiving this combination in study of Pace et al. Given the additive effect of Paclitaxel and
Cisplatin as causative agents of CIPN, we observed conflicting role of Vitamin E in preventing CIPN.
Contrary to Argyriou et al and Pace et al, Kottschade et al did not report protective role of vitamin E in
CIPN.Patientswere divided into two age groups with 39% patients in ≤50 age group and 61% in ≥50 age group. [10]
Our patients had mean age of 49.2 ± 7.90.Their study population was much bigger (n=207) as compared to our 40
patients.[10] Their study population received taxanes, cisplatin, carboplatin and oxaliplatin either alone or in
combination.[10]Patients were givenVitamin E 400 mg twice a day. [10] They used patient questionnaire to detect
neurotoxicity while we studied neuropathy by TNSn score which gives an objective assessment of CIPN. Most of
the patients received single agent chemotherapy and combinations were used in 11 % patients as compared to 42.5
% in our study. The common finding between our study was the early resolution of neuropathy in vitamin E
receiving group, suggesting its role in early recovery. [10]
Conclusion:Prevention and treatment of CIPN is a key area of research with cytotoxic agents known to cause it. Our study
showed a protective role of vitamin E profoundly in patients receiving single agent paclitaxel followed by paclitaxel
and cisplatin regimen where the recovery from CIPN was much better as compared to control arm. This is an
exciting finding as early resolution of neuropathy will also improve quality of life. This finding of quicker recovery
could be the trigger for further exploring role of nutraceutical in helping mitigate the CIPN.There were some short
comings in our study including shorter follow up and smaller study size. The study population could be followed up
further to see rate of recovery of CIPN in both the arms. We recommend testing these results in larger samplesto
validate the results of our study.Even larger doses of Vitamin E could be given to see safety and enhanced role in
recovery ofCIPN.
Conflict Of Interest:
Nil
Funding:
None
1264
ISSN: 2320-5407
Int. J. Adv. Res. 8(06), 1260-1265
References:1.
2.
3.
4.
5.
6.
7.
8.
9.
Park SB, Goldstein D, Krishnan A V, Lin CS, Friedlander ML, Cassidy J, et al. Chemotherapy-induced
peripheral neurotoxicity: A critical analysis. CA Cancer J Clin [Internet] 2013;63(6):419–37. Available from:
https://www.ncbi.nlm.nih.gov/pubmed/24590861
Addington J, Freimer M. Chemotherapy-induced peripheral neuropathy: an update on the current
understanding. F1000Research [Internet] 2016;5(F1000 Faculty Rev):1466. Available from:
http://f1000research.com/articles/5-1466/v1
Hershman DL, Lacchetti C, Dworkin RH, Lavoie Smith EM, Bleeker J, Cavaletti G, et al. Prevention and
management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American society of
clinical oncology clinical practice guideline [Internet]. J. Clin. Oncol.2014;32(18):1941–67. Available from:
http://ascopubs.org/doi/10.1200/JCO.2013.54.0914
Seretny M, Currie GL, Sena ES, Ramnarine S, Grant R, Macleod MR, et al. Incidence, prevalence, and
predictors of chemotherapy-induced peripheral neuropathy: A systematic review and meta-analysis. Pain
[Internet] 2014;155(12):2461–70. Available from: http://dx.doi.org/10.1016/j.pain.2014.09.020
Jaggi AS, Singh N. Mechanisms in cancer-chemotherapeutic drugs-induced peripheral neuropathy [Internet].
Toxicology2012;291(1–3):1–9. Available from: http://dx.doi.org/10.1016/j.tox.2011.10.019
Beijers AJM, Jongen JLM, Vreugdenhil G. Chemotherapy-induced neurotoxicity: The value of neuroprotective
strategies [Internet]. Neth. J. Med.2012;70(1):18–25. Available from: http://njmonline.nl/getpdf.php?id=1132
Schloss J, Colosimo M, Vitetta L. New Insights into Potential Prevention and Management Options for
Chemotherapy-Induced Peripheral Neuropathy. Asia-Pacific J Oncol Nurs [Internet] 2016;3(1):73. Available
from: http://www.apjon.org/text.asp?2016/3/1/73/170977
Ewertz M, Qvortrup C, Eckhoff L. Chemotherapy-induced peripheral neuropathy in patients treated with
taxanes and platinum derivatives [Internet]. Acta Oncol. (Madr).2015;54(5):587–91. Available from:
http://www.tandfonline.com/doi/full/10.3109/0284186X.2014.995775
Izycki D, Niezgoda AA, Kaźmierczak M, Piorunek T, Izycka N, Karaszewska B, et al. Chemotherapy-induced
peripheral neuropathy - diagnosis, evolution and treatment [Internet]. Ginekol. Pol.2016;87(7):516–21.
Available
from:
https://www.researchgate.net/publication/306020496_Chemotherapyinduced_peripheral_neuropathy_-_diagnosis_evolution_and_treatment
10. Kottschade LA, Sloan JA, Mazurczak MA, Johnson DB, Murphy BP, Rowland KM, et al. The use of vitamin E for the
prevention of chemotherapy-induced peripheral neuropathy: results of a randomized phase III clinical trial. Support Care
Cancer [Internet] 2011;19(11):1769–77. Available from: http://link.springer.com/10.1007/s00520-010-1018-3
11. Argyriou AA, Kyritsis AP, Makatsoris T, Kalofonos HP. Chemotherapy-induced peripheral neuropathy in adults: A
comprehensive update of the literature. Cancer Manag. Res.2014;6(1):135–47.
12. Smith EML, Beck SL, Cohen J. The Total Neuropathy Score: A Tool for Measuring Chemotherapy-Induced
Peripheral
Neuropathy.
Oncol
Nurs
Forum
[Internet]
2008;35(1):96–102.
Available
from:
http://onf.ons.org/onf/35/1/total-neuropathy-score-tool-measuring-chemotherapy-induced-peripheral-neuropathy
13. Huang H, He M, Liu L, Huang L. Vitamin E does not decrease the incidence of chemotherapy-induced peripheral
neuropathy: a meta-analysis. Współczesna Onkol [Internet] 2016;3(20):237–41. Available from:
http://www.termedia.pl/doi/10.5114/wo.2016.61567
14. Cavaletti G, Frigeni B, Lanzani F, Piatti M, Rota S, Briani C, et al. TheTotal Neuropathy Score as an assessment tool for
grading the course of chemotherapy-induced peripheral neurotoxicity : comparison with the National Cancer InstituteCommonToxicity Scale. journel Peripher Nerv Syst [Internet] 2007;215(12):210–5. Available from:
http://onlinelibrary.wiley.com/doi/10.1111/j.1529-8027.2007.00141.x/epdf
15. Issar T, Arnold R, Kwai NCG, Pussell BA, Endre ZH, Poynten AM, et al. Clinical Neurophysiology The utility of the Total
Neuropathy Score as an instrument to assess neuropathy severity in chronic kidney disease : A validation study. Clin
Neurophysiol [Internet] 2018;129(5):889–94. Available from: https://doi.org/10.1016/j.clinph.2018.02.120
16. Moazeni S, Cadeiras M, Yang EH, Deng MC, Nguyen K-L. Anthracycline induced cardiotoxicity: biomarkers and “Omics”
technology in the era of patient specific care. Clin Transl Med 2017;6(1).
17. Wozniak KM, Vornov JJ, Wu Y, Liu Y, Carozzi VA, Rodriguez-Menendez V, et al. Peripheral Neuropathy Induced by
Microtubule-Targeted Chemotherapies: Insights into Acute Injury and Long-term Recovery. Cancer Res [Internet]
2018;78(3):817–29. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5811354/pdf/nihms923465.pdf
18. Staff NP, Grisold A, Grisold W, Windebank AJ. Chemotherapy-induced peripheral neuropathy: A current review. Ann
Neurol 2017;81(6):772–81.
19. Pace A, Savarese A, Picardo M, Maresca V, Pacetti U, Del Monte G, et al. Neuroprotective effect of vitamin E
supplementation in patients treated with cisplatin chemotherapy. J Clin Oncol 2003;21(5):927–31.
20. Argyriou AA, Chroni E, Koutras A, Iconomou G, Papapetropoulos S, Polychronopoulos P, et al. Preventing PaclitaxelInduced Peripheral Neuropathy: A Phase II Trial of Vitamin E Supplementation. J Pain Symptom Manage 2006;32(3):237–
44.
1265